Celgene pays $450m for AZ's MEDI4736 in blood cancers; AZ signs $250m+ Innate deal
This article was originally published in Scrip
Executive Summary
Celgene is paying AstraZeneca $450m up front in order to develop the UK drug maker's anti-PD-L1 product MEDI4736 in a range of blood cancers – a partnership Celgene thinks could be a "meaningful" driver of growth past 2020.
You may also be interested in...
Innate Pursues Anti-Leukemic In EU
Innate Pharma pursues refractory hairy cell leukemia opportunity with first-in-class CD22-directed immunotoxin, moxetumomab pasudotox-tdfk.
Innate Pharma's Expanded IO AstraZeneca Deal Jump-Starts US Ambitions
France's Innate Pharma gets a boost to its plans to become a fully integrated biotech by forging a long-term immuno-oncology development partnership with AstraZeneca, and the setting up of a commercialization team in the US.
Podcast: Creating A Digital Biotech Story
In this latest instalment of the In Vivo podcast Daniel Lofaso, CEO of Digital Elevator, talks about the common mistakes biotech companies make when trying to build their brand, how to connect with varied audiences and key trends the industry should keep track of in digital marketing.